行情

ADMS

ADMS

Adamas Pharma
NASDAQ

实时行情|Nasdaq Last Sale

3.030
+0.190
+6.69%
交易中 15:35 04/08 EDT
开盘
2.860
昨收
2.840
最高
3.070
最低
2.800
成交量
34.89万
成交额
--
52周最高
7.78
52周最低
1.900
市值
8,487.89万
市盈率(TTM)
-0.7969
分时
5日
1月
3月
1年
5年

分析师评级

10位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测ADMS价格均价为12.69,最高价位45.00,最低价为3.000。

EPS

ADMS 新闻

更多
  • 美联储会议纪要:经济前景面临“极大程度”不确定性
  • 新浪美股 · 1小时前
  • 经济复苏为时尚早 全球市场持续震荡 欧股收盘走低
  • 新浪财经综合 · 1小时前
  • 调查:四分之一的美国人因疫情封锁措施失业或减薪
  • 新浪美股 · 1小时前
  • 美国调查丨快递小哥不干了!
  • 央视 · 2小时前

所属板块

生物技术和医学研究
+3.10%
制药与医学研究
+2.98%

热门股票

代码
价格
涨跌幅

ADMS 简况

Adamas Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues. It has developed a portfolio of chrono-synchronous therapies to address chronic neurologic disorders. Its first product candidate is ADS-5102, a chrono-synchronous amantadine therapy, for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD). It has completed Phase II proof-of-concept study of ADS-5102 in these patients. Its Phase III clinical program included three placebo-controlled trials: EASED, EASE LID and EASE LID 3. Its second product candidate is ADS-4101, an extended-release version of single-agent compound for the treatment of epilepsy (partial onset seizures).
展开

微牛提供Adamas Pharmaceuticals Inc(NASDAQ-ADMS)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的ADMS股票新闻,以帮助您做出投资决策。